Maternal and fetal outcome Our Study with patients on insulin glargine Prior studies with patients on NPH*
Intrauterine deaths {1/88} 1.1%(-1.0, 3.2) {3/172} 1.7% (-0.23,3.63) **
Preeclampsia {7/92} 7.6%(2.2,13.0) {10/371}10.7% (7.36,13.8)
Cesarean section {40/88} 45.5% (5.1,55.9) {231/324} 71% (66.0,75.9)
Maternal hypoglycemia {28/92} 31%(21.6,40.4) {20/205} 9.75% (4.28,15.2)
Mean gestational (±SD; weeks) 36.2 ± 4.38 36.3 ± 1.0
Five minute Apgar score <7 {3/64} 4.7%(-0.48,9.88) {4/183} 2.1 % (0.03,4.17)
Macrosomia (>4000 grams) {8/65} 12.3 %(4.4,20.2) {26/166} 15.6 % (10.9,21.11)
Shoulder Dystocia {2/92} 2.1%(-0.82,5.02) {7/98} 7.14% (2.09,12.19)
Fetal Hypoglycemia {6/92} 6.5% (1.47,11.5) {66/346} 19% (14.87,23.13)


Data is presented as mean with SD or as a percentage.
In braces {events/total number of patients studied}
In Parenthesis (95% confidence interval Lower and upper limit)
Data presented is unadjusted
Abbreviation: NPH: Neutral Protamine Hagedorn
** Fetal outcome reported was perinatal mortality
*Ref: [10,11]
Table 2: Comparison of Maternal and fetal outcomes comparing our study with patients on insulin glargine with prior studies with patients on NPH.